Article

Study: moxifloxacin yields higher peak levels than gatifloxacin

Fort Lauderdale, FL-In a comparison of penetration of moxifloxacin HCl ophthalmic solution 0.5% (Vigamox, Alcon Laboratories) and gatifloxacin ophthalmic solution 0.3% (Zymar, Allergan) in a human cornea transplant model, mean peak levels of moxifloxacin were higher than those of gatifloxacin in corneal tissue and the aqueous humor, said Edward Holland, MD.

"Moxifloxacin had superior penetration over gatifloxacin," said Dr. Holland, director, Cornea Services, Cincinnati Eye Institute, and professor of ophthalmology, University of Cincinnati, Cincinnati, OH. "We found a three-fold greater level of moxifloxacin (48.5 μg/g) in the corneal stroma and anterior chamber when compared with gatifloxacin (15.7 μg/g). If you looked at the epithelium and endothelium, it was seven-fold and 10-fold higher."

Levels of moxifloxacin and gatifloxacin in the epithelium were 81.2 μg/g and 12.3 μg/g, respectively. In the endothelium, the respective levels were 76.1 μg/g and 7.3 μg/g. The mean peak level of moxifloxacin in the aqueous humor was also approximately three-fold higher than the level of gatifloxacin.

After aqueous humor sampling and excision of the corneal button, the samples were placed on dry ice and shipped for analysis. The corneas were dissected into epithelium, stroma, and endothelium and assayed using a validated simultaneous HPLC-fluorescence method.

The study also shows that high levels of penetration can be achieved with one drop of a fluoroquinolone antibiotic, Dr. Holland said.

"These are further data supporting why you can consider changing your preoperative regimen to administer the antibiotic the day of surgery," he said. "With preoperative dosing of just one drop, you can achieve very high levels of moxifloxacin in the cornea and the anterior chamber. It well exceeds the MIC 90s for all the major pathogens that we're most concerned about for endophthalmitis and keratitis."

The data were presented in a poster at the annual meeting of the Association for Research in Vision and Ophthalmology.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.